Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

The burden of liver disease in Europe continues to grow. We aimed to describe the
epidemiology of liver diseases and their risk factors in European countries, identifying public …

Metformin is a well-known anti-diabetic drug that has been repurposed for several emerging
applications, including as an anti-cancer agent. It boasts the distinct advantages of an …

Rates of obesity and diabetes have increased significantly over the past decades and the
prevalence is expected to continue to rise further in the coming years. Many observations …

The relative insufficiency of insulin secretion and/or insulin action causes diabetes.
However, obesity and type 2 diabetes mellitus can be associated with an absolute increase …

Aging has been targeted by genetic and dietary manipulation and by drugs in order to
increase lifespan and health span in numerous models. Metformin, which has demonstrated …

Aims/hypothesis Metformin is the most-prescribed oral medication to lower blood glucose
worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in …

Multiple epidemiological studies have documented an association between metformin, used
for treatment of type 2 diabetes, and reduced cancer incidence and mortality. Cell line …

Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for
type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose …

Insulin resistance (IR) and hyperinsulinemia are hallmarks of the metabolic syndrome, as
are central adiposity, dyslipidemia, and a predisposition to type 2 diabetes, atherosclerotic …